Please upgrade to Flash 8 or higher.
Orexigen® is a biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders, including obesity.
Orexigen’s lead combination product candidates targeted for obesity are Contrave®, which is in Phase III clinical trials, and Empatic™ which is in the later stages of Phase II clinical development. In addition, Orexigen continues to explore product candidates addressing central nervous system disorders.
-
Product Candidates
Learn how our products go beyond the traditional approach to weight reduction.
-
Clinical Trials
Get up to date details of all our trials.
-
Our Technology
Discover what makes our technology and processes different.
-
Latest News
June 12, 2008 – Orexigen® Therapeutics to Discuss Two Advanced-Stage Obesity Products That Target the Brain's Critical Role in Regulating Body Weight
